Acrivon Therapeutics (ACRV) Current Assets (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Current Assets of $99.2 million for Q1 2026, down 34.43% year-over-year from $151.3 million in Q1 2025, and down 17.62% quarter-over-quarter from $120.4 million in Q4 2025.
Acrivon Therapeutics (ACRV) Current Assets (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Current Assets for 6 consecutive years, with $99.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 34.43% year-over-year to $99.2 million; the TTM figure through Mar 2026 stood at $99.2 million (down 34.43% YoY), while the FY2025 annual figure was $120.4 million, down 33.69% from the prior year.
- Current Assets retreated to $99.2 million in Q1 2026 per ACRV's latest filing, from $120.4 million in the prior quarter.
- Across five years, Current Assets topped out at $189.0 million in Q3 2024 and bottomed at $78.7 million in Q3 2022.
- Historically, Current Assets has averaged $137.8 million across 5 years, with a median of $132.1 million in 2022.
- Annual changes were most pronounced in 2023 — Current Assets jumped 83.66% — and 2026, when it sank 34.43%.
- Acrivon Therapeutics' Current Assets stood at $132.1 million in 2022, then declined by 1.82% to $129.7 million in 2023, then surged by 40.05% to $181.6 million in 2024, then plunged by 33.69% to $120.4 million in 2025, then fell by 17.62% to $99.2 million in 2026.
- Business Quant data shows ACRV's Current Assets at $99.2 million in Q1 2026, $120.4 million in Q4 2025, and $130.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | 91.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.49 Mn |
| Mar 31, 2026 | 99.22 Mn |
| Dec 31, 2025 | 120.45 Mn |
| Sep 30, 2025 | 130.36 Mn |
| Jun 30, 2025 | 138.41 Mn |
| Mar 31, 2025 | 151.33 Mn |
| Dec 31, 2024 | 181.63 Mn |
| Sep 30, 2024 | 188.98 Mn |
| Jun 30, 2024 | 182.36 Mn |
| Mar 31, 2024 | 112.14 Mn |
| Dec 31, 2023 | 129.69 Mn |
| Sep 30, 2023 | 144.49 Mn |
| Jun 30, 2023 | 153.28 Mn |
| Mar 31, 2023 | 123.96 Mn |
| Dec 31, 2022 | 132.10 Mn |
| Sep 30, 2022 | 78.67 Mn |
| Dec 31, 2021 | 100.41 Mn |